News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Putney, Inc. Enters the $175M Annual Veterinary NSAID Market



6/24/2009 8:23:24 AM

Makes Treatment More Affordable to Pet Owners

PORTLAND, Maine, June 23 /PRNewswire/ -- Putney, Inc., a pharmaceutical company focused on the development of generic drugs for pets, has launched carprofen caplets, a bioequivalent generic version of the canine medication Rimadyl(R) caplets. Putney's carprofen is offered so as to cost at least 25% less to veterinarians than its branded competitor -- allowing veterinarians to provide savings for pet owners and increasing profits to veterinary practices in this tough economy.

Carprofen is widely used in dogs for the relief of pain and inflammation associated with osteoarthritis, as well as the control of post-operative pain associated with soft tissue and orthopedic surgeries. In a recent survey conducted by Advanstar Veterinary Healthcare Communications, 96% of responding veterinarians nationwide indicated they prescribe and dispense branded carprofen medications. Putney's carprofen caplets have demonstrated bioequivalence to Pfizer's Rimadyl(R) caplets in an FDA approved study and will be available in the same strengths (25mg, 75mg and 100mg caplets) and convenient packaging as the branded drug.

In the Advanstar survey, 80% of companion animal veterinarians surveyed across the country responded that they would feel comfortable switching to generic carprofen caplets and 88% believe that pet owners are receptive to switching to the generic.

In general, in spite of expired patents on many veterinary drugs, few cost-saving generics have been developed and approved by the FDA for pets. "With carprofen caplets, Putney is delivering a high quality, bioequivalent generic option to veterinarians to help pet owners afford to treat pets," said Jean Hoffman, CEO and founder of Putney. Carprofen caplets are the first FDA approved veterinary generic in Putney's pipeline of veterinary generic and specialty drugs. Ms. Hoffman says Putney expects future sales of more than $20 million annually for carprofen products, subject to FDA approval for the Company's generic drug applications for various forms of carprofen. Putney's carprofen caplets are available from selected licensed veterinary distributors such as First Veterinary Supply in Michigan -- and directly from Putney for large veterinary practices.

Putney, Inc., is a pharmaceutical company that listens to companion animal veterinarians and responds to their needs -- making affordable drugs available, and developing products that address common concerns such as compliance, dosing and palatability. Putney empowers veterinarians with prescribing choices that allow them to pursue the best course of treatment for improved compliance, more satisfied pet owners and happy pets. Learn more at www.putneyvet.com.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=88021

CONTACT: Christina Perkins, Vice President, Marketing & Communications of
Putney, Inc., +1-207-828-0880, Christina.Perkins@PutneyVet.com

Web site: http://www.putneyvet.com/


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES